With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.
Into a 40-mL round-bottom flask, was placed 4-(4-((4?-chloro-5, 5-dimethyl-3, 4, 5, 6-tetrahydro-[l, 1?-biphenyl] -2-yl)methyl)piperazin-l-yl)- 2-(3-methoxy-3,4-dihydro-2H-pyrrolo[3?,2?:5,6]pyrido[2,3-b][l,4]oxazepin-l(7H)- yl)benzoic acid (50 mg, 0.08 mmol, 1 equiv), DCM (3 mL), 3-nitro-4-[[(oxan-4- yl)methyl]amino]benzene-l-sulfonamide (25.2 mg, 0.08 mmol, 1.00 equiv), EDCI (30.6 mg, 0.16 mmol, 2 equiv), DMAP (39.0 mg, 0.32 mmol, 4 equiv). The resulting solution was stirred for overnight at 25 degrees C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloro methane/methanol (10: 1). The crude product was purified by Flash- Prep-HPLC with the following conditions (IntelFlash-l): Column, C18 reversed phase column; mobile phase, Water (10MMOF/F NH4HC03+0.05%NH3.H20) and CH3CN (20.0% CH3CN up to 90.0% in 30 min); Detector, UV 220 nm. This resulted in 32 mg (40.0%) of 4-(4-((4?-chloro-5,5-dimethyl-3, 4,5,6- tetrahydro- [1,1? -biphenyl] -2-yl)methyl)piperazin- 1 -yl) -2-(3 -methoxy-3 ,4-dihydro-2H- pyrrolo[3?,2?:5,6]pyrido[2,3-b][l,4]oxazepin-l(7H)-yl)-N-((3-nitro-4-(((tetrahydro-2H- pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide as a yellow solid. FC-MS: (ES, m/z): M+l=953, R,T= 3.44 min. 1H NMR (300 MHz, DMSO-d6, ppm) d 11.00 (ds, 1H), 8.56 (s, 2H), 7.47-7.44 (m, 2H), 7.36-7.33 (m, 2H), 7.08-7.04 (m, 3H), 6.78-6..65 (m, 2H), 6.57-6.54 (m, 1H), 6.43 (s, 1H), 6.04 (s, 1H), 4.05-3.15 (m, 20H), 3.13 (s, 1H), 2.70-2.35 (m, 4H), 2.03 (s, 3H), 1.92-1.90 (m, 1H), 1.89-1.87 (m, 2H), 1.71-1.67 (m, 2H), 1.53-1.45 (m, 3H), 0.97 (s, 6H, 1228779-96-1
The synthetic route of 1228779-96-1 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; NEWAVE PHARMACEUTICAL INC.; CHEN, Yi; (475 pag.)WO2020/41406; (2020); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics